<DOC>
	<DOC>NCT00440154</DOC>
	<brief_summary>The primary objective of this study is to assess the effect of AVE5530 on LDL-C levels over a period of 4 weeks. The secondary objectives are to assess the effects of AVE5530 on other lipid plasma levels and the safety and tolerability of AVE5530.</brief_summary>
	<brief_title>A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Patients with mild to moderate primary hypercholesterolemia with stabilized LDLC baseline ≥130 mg/dL and ≤ 250 mg/dL (≥ 3.36 mmol/L and ≤ 6.46 mmol/L) Male aged ≥ 18 years or postmenopausal women at screening Presence of any clinically significant endocrine disease known to influence serum lipids or lipoproteins Patients with type 1 diabetes Presence or history of cancer within the past five years Triglycerides ≥ 300 mg/dL (3.39 mmol/L) Fasting plasma glucose &gt; 160 mg/dL (8.9 mmol/L) Impaired kidney function and active liver disease Within one month prior to screening visit and/or at the time or after the screening visit, administration of any lipid lowering treatment Creatine Kinase &gt; 2xUpper Limit of Normal range The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>